Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129062) titled 'The efficacy and safety of sequential IL-12/23p40 inhibitor and IL-17A inhibitor in the treatment of moderate to severe plaque psoriasis: A multicenter randomized controlled clinical trial' on July 30.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Condition:
Psoriasis
Intervention:
Ustekinumab monotherapy group:Ustekinumab
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-08-03
Target Sample Size: Ustekinumab monotherapy group:53;Ustekinumab-to-Ixekizumab sequential-the...